Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a combination treatment for men and post-menopausal women with hormone receptor positive HR, HER2-negative advanced or metastatic breast cancer that has specific alterations in the PI3K pathway, such as mutations in the PIK3CA gene, PTEN loss, or AKT1 mutation. This Phase 1b2, open-label pilot study aims to determine the safety of evexomostat combined with either alpelisib or capivasertib plus fulvestrant, measure the severity and number of hyperglycemic events, and assess the anti-tumor effects of these triplet therapies. Participants will first receive evexomostat plus fulvestrant for 14 days before adding either alpelisib or capivasertib, depending on the oncologists choice, forming the triplet therapy. Treatment cycles last 28 days, and doses of evexomostat may be adjusted based on safety data. Patients may continue the triplet therapy for up to seven cycles, or longer if clinical benefit is observed, with ongoing safety and efficacy monitoring. During the study, patients will undergo tumor assessments and monitoring of hyperglycemic events, glucose control, insulin resistance, and various biomarkers related to tumor and metabolic activity. Safety data, adverse events, and quality of life will be evaluated up to 42 to 48 months. Participants must attend scheduled visits and comply with fasting requirements on designated days. The study allows continuation of therapy until disease progression, unacceptable toxicity, or withdrawal.
Actively Recruiting
Researchers are evaluating QXL138AM, a biological treatment given by intravenous infusion every two weeks, in adults with locally advanced, unresectable, or metastatic solid tumors or multiple myeloma. This first-in-human Phase 1a1b study aims to assess the safety, how the drug moves through the body, and early signs of anti-tumor activity. The study is open-label and conducted across multiple centers, sponsored by Nammi Therapeutics Inc. The study is divided into two main parts, each with two sub-parts. Part A involves dose escalation Part A1 enrolls participants with various advanced solid tumors and uses a modified 33 dose escalation design to find the recommended dose, while Part A2 focuses on dose escalation in multiple myeloma, starting once the dose for solid tumors is identified or if activity is seen. Part B involves dose expansion, exploring safety and anti-tumor effects at the recommended doses in larger groups of participants with solid tumors Part B1 and multiple myeloma Part B2. The infusion is administered over 30 to 60 minutes. Participants will undergo screening to confirm eligibility, including measurable disease and adequate organ function. Throughout the study, safety is closely monitored by tracking adverse events and measuring drug levels in the blood. Anti-tumor activity will be assessed during the dose expansion phase. The study includes an estimated duration of about 3.5 years to collect comprehensive safety and pharmacokinetic data. Participants will be followed regularly with assessments to evaluate treatment effects and monitor for any side effects.